Detail
| LncRNA Name | LINC00152 |
| Synonyms | CYTOR, C2orf59, LINC00152, NCRNA00152, MGC4677 |
| Region | GRCh38_2:87454781-87636740 Sequence |
| Ensembl | ENSG00000222041 |
| RefSeq | NR_024204 |
| Circulating | ✘ |
| Drug-resisitant | ✔ |
| Prognostic | ✔ |
| MiRNA | ✔ |
| Variant | ✘ |
| TF | ✘ |
| Methylation | ✘ |
| Cancer Name | colon cancer |
| ICD-0-3 | C18 |
| Methods | qPCR, Western blot, Luciferase reporter assay, Cell proliferation assay etc. |
| Sample | colon cancer tissues, cell lines (SW480, Caco2, SW620 and HT29) |
| Expression Pattern | up-regulated |
| Function Description | Elevated expression of Linc00152 was observed by using qRT-PCR in colon cancer tissues when compared with adjacent normal mucosa. Linc00152 as a candidate prognostic indicator of outcome and drug responsiveness in colon cancer patients, and the involvement of competing endogenous RNAs mechanism in Linc00152/miR-193a-3p/ERBB4/AKT signaling axis may provide a novel choice in the investigation of drug resistance. |
| Pubmed ID | 27633443 |
| Year | 2016 |
| Title | Linc00152 Functions as a Competing Endogenous RNA to Confer Oxaliplatin Resistance and Holds Prognostic Values in Colon Cancer. |
| External Links |
| Links for LINC00152 | GenBank HGNC lncrnadb Noncode |
| Links for colon cancer | Omim Cosmic |
CopyRight © College of Bioinformatics Science and Technology, Harbin Medical University, China.